Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know

The CEO sold 15,000 shares for $1.4 million on August 3, 2026.

This disposition reduced the executive's direct equity position by 3%.

The transaction was executed under a Rule 10b5-1 trading plan established on June 20, 2025.

CEO Cameron Turtle reported a sale of 15,000 shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) in a recent SEC Form 4 filing .

Transaction value based on SEC Form 4 weighted average sale price ($95.51); post-transaction value based on the August 3 market close ($94.93).

Spyre Therapeutics is a clinical-stage biotechnology firm with a market capitalization of $9.1 billion, demonstrating substantial investor confidence in its immunology-focused pipeline. The company is leveraging targeted monoclonal antibody technology to address inflammatory bowel disease, a chronic condition affecting millions of patients globally. Spyre is positioned within the competitive biotechnology landscape focused on precision immunotherapy development.

The contrast worth noticing is that Turtle sold 15,000 shares while holding on to more than 567,000, so the sale amounts to a rounding error against what he kept, and the plan behind it dates back over a year. Plus, part of his position vests in monthly slivers through November, which is the kind of structure that produces routine, scheduled sales regardless of where the stock trades, so reading intent into it would be a mistake for a founder-level holder this committed. The company gives shareholders plenty to focus on instead. Spyre's two lead antibodies for ulcerative colitis both cleared their main goals in mid-stage testing this year, with SPY001 delivering 40% clinical remission and SPY002 reaching 33% at 12 weeks, results the company frames as best-in-class potential. It has run its trials ahead of schedule, with a rheumatoid arthritis readout and another colitis candidate's data both due in September. Relatively to this type of sale, those looming readouts are what actually matter here, because a stock that has already climbed this far now will rely heavily on fresh data to justify the price.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Spyre Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.